Policy | August 06, 2021
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
CDSCO to fast-track trials and approval for COVID19 vaccine
CDSCO to fast-track trials and approval for COVID19 vaccine
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The product patent has been already filed under fast track approval
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The agreement will help ensure wider reach and access to patients in India
Subscribe To Our Newsletter & Stay Updated
